NET PROFIT (x1000 SEK)
EMPLOYEES
Biocell AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
820
|
1
|
2,005 |
| Earnings before taxes |
-751
|
106
|
1,193 |
| EBITDA |
-784
|
-716
|
-663 |
| Total assets |
13,958
|
14,373
|
15,569 |
| Current assets |
4,275
|
8,099
|
10,831 |
| Current liabilities |
1,955
|
1,936
|
2,964 |
| Equity capital |
12,003
|
12,437
|
12,605 |
| - share capital |
1,000
|
1,000
|
1,000 |
| Employees (average) |
1
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
86.0%
|
86.5%
|
81.0% |
| Turnover per employee | 0 | ||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
0.5%
|
0.7%
|
20.5% |
| Current ratio |
218.7%
|
418.3%
|
365.4% |
| Return on equity (ROE) |
-6.3%
|
0.9%
|
9.5% |
| Change turnover |
0
|
0
|
-38,296 |
| Change turnover % | -100% | ||
| Chg. No. of employees |
1
|
0
|
-1 |
| Chg. No. of employees % | -100% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.